CA
AVXL icon

Cliff Asness’s Anavex Life Sciences AVXL Stock Holding History

Cliff Asness’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49M Buy
963,014
+206,222
+27% +$610K ﹤0.01% 2477
2026
Q1 		$2.32M Buy
756,792
+606,977
+405% +$2.63M ﹤0.01% 2244
2025
Q4 		$533K Buy
149,815
+121,779
+434% +$746K ﹤0.01% 2873
2025
Q3 		$250K Sell
28,036
-1,027
-4% -$10.4K ﹤0.01% 3168
2025
Q2 		$268K Sell
29,063
-78
-0.3% -$666 ﹤0.01% 2923
2025
Q1 		$250K Sell
29,141
-19,174
-40% -$181K ﹤0.01% 2773
2024
Q4 		$519K Sell
48,315
-88,329
-65% -$679K ﹤0.01% 2235
2024
Q3 		$776K Buy
136,644
+91,425
+202% +$527K ﹤0.01% 1970
2024
Q2 		$191K Buy
45,219
+26,821
+146% +$108K ﹤0.01% 2433
2024
Q1 		$93.6K Sell
18,398
-203
-1% -$1.14K ﹤0.01% 2344
2023
Q4 		$173K Buy
18,601
+1,809
+11% +$12.5K ﹤0.01% 2234
2023
Q3 		$110K Buy
16,792
+3,459
+26% +$27.5K ﹤0.01% 2219
2023
Q2 		$108K Buy
13,333
+892
+7% +$7.64K ﹤0.01% 2140
2023
Q1 		$107K Sell
12,441
-12,937
-51% -$129K ﹤0.01% 2113
2022
Q4 		$235K Sell
25,378
-393
-2% -$4.2K ﹤0.01% 2039
2022
Q3 		$266K Buy
25,771
+1,469
+6% +$15.5K ﹤0.01% 1975
2022
Q2 		$243K Sell
24,302
-4,117
-14% -$39K ﹤0.01% 1930
2022
Q1 		$350K Sell
28,419
-8,061
-22% -$99.1K ﹤0.01% 1930
2021
Q4 		$633K Buy
36,480
+5,854
+19% +$111K ﹤0.01% 1751
2021
Q3 		$550K Buy
30,626
+1,431
+5% +$28.5K ﹤0.01% 1827
2021
Q2 		$667K Buy
29,195
+776
+3% +$11.5K ﹤0.01% 1775
2021
Q1 		$425K Sell
28,419
-11,213
-28% -$122K ﹤0.01% 1897
2020
Q4 		$214K Buy
39,632
+1,694
+4% +$8.93K ﹤0.01% 2075
2020
Q3 		$173K Buy
37,938
+1,923
+5% +$8.28K ﹤0.01% 2082
2020
Q2 		$177K Buy
36,015
+15,456
+75% +$58.4K ﹤0.01% 2012
2020
Q1 		$65K Buy
+20,559
New +$71.6K ﹤0.01% 1997

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cliff Asness's AVXL Position: Q2 2026 in Review

Cliff Asness increased its Anavex Life Sciences (AVXL) stake by 27% in Q2 2026, buying an estimated $610K and bringing the position to 963,014 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

Cliff Asness first reported a position in AVXL in Q1 2020 and has held it in 26 quarters since. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Cliff Asness held 963,014 shares of Anavex Life Sciences worth $2.49M as of Q2 2026.
  • Cliff Asness bought 206,222 Anavex Life Sciences shares in Q2 2026, an estimated $610K.
  • Anavex Life Sciences made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2477 holding.
  • Cliff Asness first reported a position in Anavex Life Sciences in Q1 2020 and has held it in 26 quarters since.
  • 177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.